Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

YOU WONT BELIEVE: Atai life sciences experimental depression drug shows sustained benefit in treatment resistant patients | Mind Blowing Facts

Pharmacist,Holding,1,Tablets,(single,Dose,),Of,Contraceptive,Pill

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).

Patients were given an 8 mg dose of BPL-003 followed by a 12 mg dose two weeks later.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.